AIMSPRO in Established Diffuse Cutaneous Systemic Sclerosis
Status:
Unknown status
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
To study the safety and tolerability of a hyperimmune goat serum product (AIMSPRO) in the
treatment of systemic sclerosis (SSc) through a period of 26 weeks of study participation.
The secondary objective of the study is to assess the efficacy of AIMSPRO as a therapeutic
agent for SSc using inter alia the SSc-HAQ questionnaire and the modified Rodnan skin score.